Literature DB >> 15182764

Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure.

Andreas Krack1, Barbara M Richartz, Anja Gastmann, Kasia Greim, Ulrich Lotze, Stefan D Anker, Hans R Figulla.   

Abstract

AIMS: The aim of this study was to investigate mesenteric ischaemia by determining intragastric PCO(2) (iPCO(2)) with gastric tonometry during rest and exercise stress testing in patients with chronic heart failure (CHF). In CHF inflammatory immune activation is hypothesized to result from a chronic endotoxin challenge due to bacterial translocation of hypoperfused intestinal mucosa. METHODS AND
RESULTS: In 10 patients with CHF and ten healthy controls a tonometry catheter was inserted into the stomach. IPCO(2) was measured at rest and during bicycle exercise every 5 min. At rest arterial pCO(2) (aPCO(2)), intragastric pCO(2) (iPCO(2)) and the intragastric/arterial gap did not differ between patients and controls. During low level exercise (25 W), patients showed an increase in iPCO(2) compared to resting iPCO(2), whereas controls did not show an increase in iPCO(2) (change in iPCO(2): 12+/-2% vs. 1+/-0.4%, P<0.001). In CHF, iPCO(2) during peak exercise was 25+/-3% higher than at rest, compared to controls (increase 2+/-1, P<0.0001).
CONCLUSIONS: Patients with CHF already at low level exercise develop an increase in iPCO(2). This is likely to reflect hypoperfusion of the intestinal mucosa, which may contribute to the development of bacterial translocation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182764     DOI: 10.1016/j.ejheart.2004.03.002

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  24 in total

Review 1.  The gut microbiome and heart failure: A better gut for a better heart.

Authors:  Maxime Branchereau; Rémy Burcelin; Christophe Heymes
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

Review 2.  Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis.

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  J Card Fail       Date:  2015-10-03       Impact factor: 5.712

Review 3.  Gut Microbiota in Cardiovascular Health and Disease.

Authors:  W H Wilson Tang; Takeshi Kitai; Stanley L Hazen
Journal:  Circ Res       Date:  2017-03-31       Impact factor: 17.367

Review 4.  Gut Microbiome and Precision Nutrition in Heart Failure: Hype or Hope?

Authors:  Thanat Chaikijurajai; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2021-02-09

Review 5.  Diagnosis and management of splanchnic ischemia.

Authors:  Jeroen-J Kolkman; Marloes Bargeman; Ad-B Huisman; Robert-H Geelkerken
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

Review 6.  Exploring the Microbiome in Heart Failure.

Authors:  Takeshi Kitai; Jennifer Kirsop; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2016-04

Review 7.  Constipation-induced pressor effects as triggers for cardiovascular events.

Authors:  Yusuke Ishiyama; Satoshi Hoshide; Hiroyuki Mizuno; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-02-13       Impact factor: 3.738

8.  Exercise-induced splanchnic hypoperfusion results in gut dysfunction in healthy men.

Authors:  Kim van Wijck; Kaatje Lenaerts; Luc J C van Loon; Wilbert H M Peters; Wim A Buurman; Cornelis H C Dejong
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

9.  Activation of a novel natriuretic endocrine system in humans with heart failure.

Authors:  Hafid Narayan; Noor Mohammed; Paulene A Quinn; Iain B Squire; Joan E Davies; Leong L Ng
Journal:  Clin Sci (Lond)       Date:  2010-03       Impact factor: 6.124

Review 10.  Gut Microbiota: A Novel Regulator of Cardiovascular Disease and Key Factor in the Therapeutic Effects of Flavonoids.

Authors:  Qinyu Li; Bing Gao; Bateer Siqin; Qian He; Ru Zhang; Xiangxi Meng; Naiheng Zhang; Na Zhang; Minhui Li
Journal:  Front Pharmacol       Date:  2021-06-16       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.